Genesco Posts 4% Revenue Gain in Q2

Genesco (GCO) reported Q2 FY2026 GAAP revenue up 4% to $546 million, largely driven by a strong 9% comparable sales gain at its Journeys banner. Despite the top-line growth, GAAP gross margin declined by 1.0 percentage point to 45.8% and non-GAAP EPS widened to ($1.14), reflecting significant margin pressures from aggressive promotional activity, particularly in the UK (Schuh), and tariff impacts across other segments. While the company raised its full-year FY2026 sales guidance, adjusted EPS guidance remained unchanged, underscoring the ongoing challenge of translating revenue growth into improved profitability amidst persistent cost and margin headwinds.

Analysis

Genesco's Q2 FY2026 results present a bifurcated picture, characterized by strong top-line momentum at its core banner offset by significant, widespread margin erosion. The company's 4% year-over-year revenue increase to $546 million was driven almost exclusively by its Journeys segment, which delivered a robust 9% gain in comparable sales and accounted for 58.3% of total revenue. This performance prompted management to raise full-year sales growth guidance to a 3%-4% range. However, this revenue strength did not translate to profitability, as GAAP gross margin contracted by 100 basis points to 45.8% and the adjusted operating margin worsened to (2.6%). The non-GAAP EPS loss widened to ($1.14) from ($0.83) a year prior. Profitability was severely impacted by a highly promotional U.K. market which crushed margins at the Schuh division, along with tariff-related costs that caused the Genesco Brands segment's operating margin to collapse from nearly 9% to 2%. Critically, the decision to hold full-year adjusted EPS guidance steady despite a higher sales outlook signals that management expects these margin pressures to persist. An 11.3% year-over-year increase in inventory to $501 million introduces further risk, potentially necessitating future markdowns if demand falters.

Key Decisions for Investors

• Investors should view the unchanged full-year EPS guidance as a key signal that ongoing margin compression from promotions and tariffs is expected to fully offset the stronger sales outlook, warranting a cautious stance.
• The 11.3% increase in inventory represents a significant risk; monitor inventory levels and gross margin performance in subsequent quarters for signs of either successful sell-through or the need for deeper, margin-eroding discounts.
• Given the stark divergence in performance, focus on segment-level data, as any investment thesis relies heavily on the continued outperformance of Journeys to counteract persistent weakness at Schuh and Johnston & Murphy.
• Consider holding off on new positions until there is clear evidence of margin stabilization, as the current dynamic suggests revenue growth is not translating into shareholder value.